These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with Yue D; Qian J; Chen Z; Zhang B; Chen P; Zhang L; Li J; Zhang H; Wang C J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33558279 [TBL] [Abstract][Full Text] [Related]
25. Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer. Pabst L; Lopes S; Bertrand B; Creusot Q; Kotovskaya M; Pencreach E; Beau-Faller M; Mascaux C Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108738 [TBL] [Abstract][Full Text] [Related]
26. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies. Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034 [TBL] [Abstract][Full Text] [Related]
27. Management of Advanced Pleural Mesothelioma-At the Crossroads. Nowak AK; Jackson A; Sidhu C JCO Oncol Pract; 2022 Feb; 18(2):116-124. PubMed ID: 34491782 [TBL] [Abstract][Full Text] [Related]
28. The next generation of immunotherapy: keeping lung cancer in check. Somasundaram A; Burns TF J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399 [TBL] [Abstract][Full Text] [Related]
29. Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy. Passaro A; Mancuso P; Gandini S; Spitaleri G; Labanca V; Guerini-Rocco E; Barberis M; Catania C; Del Signore E; de Marinis F; Bertolini F Clin Transl Oncol; 2020 Apr; 22(4):603-611. PubMed ID: 31254252 [TBL] [Abstract][Full Text] [Related]
33. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Peters S; Scherpereel A; Cornelissen R; Oulkhouir Y; Greillier L; Kaplan MA; Talbot T; Monnet I; Hiret S; Baas P; Nowak AK; Fujimoto N; Tsao AS; Mansfield AS; Popat S; Zhang X; Hu N; Balli D; Spires T; Zalcman G Ann Oncol; 2022 May; 33(5):488-499. PubMed ID: 35124183 [TBL] [Abstract][Full Text] [Related]
34. The current management and biomarkers of immunotherapy in advanced gastric cancer. Chang X; Ge X; Zhang Y; Xue X Medicine (Baltimore); 2022 May; 101(21):e29304. PubMed ID: 35623069 [TBL] [Abstract][Full Text] [Related]
35. The Current Landscape of Immune Checkpoint Blockade in Metastatic Lung Squamous Cell Carcinoma. Yuan H; Liu J; Zhang J Molecules; 2021 Mar; 26(5):. PubMed ID: 33807509 [TBL] [Abstract][Full Text] [Related]
36. Case Report: Therapeutic Response to Chemo-Immunotherapy in an Advanced Large Cell Lung Carcinoma Patient With Low Values of Multiple Predictive Biomarkers. Wang G; Chai Q; Xiao Y; Peng W; Teng M; Wang J; Lin H; Su X; Wu L Front Immunol; 2020; 11():607416. PubMed ID: 33584678 [TBL] [Abstract][Full Text] [Related]
37. Baseline extracellular vesicle TGF-β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancer. de Miguel-Perez D; Russo A; Gunasekaran M; Buemi F; Hester L; Fan X; Carter-Cooper BA; Lapidus RG; Peleg A; Arroyo-Hernández M; Cardona AF; Naing A; Hirsch FR; Mack PC; Kaushal S; Serrano MJ; Adamo V; Arrieta O; Rolfo C Cancer; 2023 Feb; 129(4):521-530. PubMed ID: 36484171 [TBL] [Abstract][Full Text] [Related]
38. Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer. Li S; Zhang C; Pang G; Wang P Front Immunol; 2020; 11():603157. PubMed ID: 33178229 [TBL] [Abstract][Full Text] [Related]
39. Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy. Harber J; Kamata T; Pritchard C; Fennell D J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34518291 [TBL] [Abstract][Full Text] [Related]